A systematic review by Mantovani et al., published in The Lancet Gastroenterology and Hepatology, evaluated three classes of diabetes drugs—peroxisome proliferator-activated receptor (PPAR) agonists, GLP-1R agonists, and SGLT-2 inhibitors—all of which demonstrated potential benefits in NAFLD treatment [18]. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.